NL-OMON34991已完成不适用
A first-in-human single-dose escalation study of the safety, pharmacokinetics and pharmacodynamics of the test drug including brain Serotonin Receptor Transporter (SERT) occupancy by Positron Emission Tomography (PET). - new drug SRD/PET study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Eli Lilly
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male, age between 18 and 65 years, BMI between 19 and 32.5 kg/m2, non-smoker or moderate smoker, at screening state of health must satisfy the entry requirements. ;Only part B:
- •Non-exposure to any radiation for diagnostic reasons during work or during participation in a medical trial in the past year, non claustrophobic.
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A FIRST-IN-HUMAN SINGLE-DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF LY2165766 INCLUDING BRAIN DOPAMINE D2 RECEPTOR OCCUPANCY BY POSITRON EMISSION TOMOGRAPHY (PET)10039628schizophreniaNL-OMON33530Chorus LRL (devisie van Eli Lilly)38
已完成
不适用
A First in Human, Single-dose Escalation Study of LY2562175 In Healthy Subjectslipidsmetabolism10013317NL-OMON33901Chorus, Lilly Research Laboratories18
进行中（未招募）
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-504403-92-00Janssen - Cilag International200
进行中（未招募）
1 期
A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisRelapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisCancerISRCTN13185938Janssen Research & Development, LLC140
终止
1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid TumorsCancerACTRN12617001181392INC Research Pty Ltd4